Satyavrat Shukla
2021
In 2021, Satyavrat Shukla earned a total compensation of $2.2M as Chief Financial Officer at Spero Therapeutics.
Compensation breakdown
| Bonus | $164,000 |
|---|---|
| Non-Equity Incentive Plan | $175,660 |
| Option Awards | $1,039,433 |
| Salary | $440,889 |
| Stock Awards | $399,994 |
| Other | $8,295 |
| Total | $2,228,271 |
Shukla received $1M in option awards, accounting for 47% of the total pay in 2021.
Shukla also received $164K in bonus, $175.7K in non-equity incentive plan, $440.9K in salary, $400K in stock awards and $8.3K in other compensation.
Rankings
In 2021, Satyavrat Shukla's compensation ranked 5,616th out of 12,405 executives tracked by ExecPay. In other words, Shukla earned more than 54.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,616 out of 12,405 | 55th |
Division Manufacturing | 2,378 out of 5,494 | 57th |
Major group Chemicals And Allied Products | 1,032 out of 2,369 | 56th |
Industry group Drugs | 921 out of 2,090 | 56th |
Industry Pharmaceutical Preparations | 663 out of 1,537 | 57th |
Source: SEC filing on August 5, 2022.
Shukla's colleagues
We found three more compensation records of executives who worked with Satyavrat Shukla at Spero Therapeutics in 2021.